Patent application number | Description | Published |
20080293725 | Prognostic Molecular Markers - The present invention relates to the use of ecteinascidin 743 in patients having certain levels of molecular markers who can predict the outcome of chemotherapy, in particular in patients having low levels of BRCA1 expression. | 11-27-2008 |
20100009013 | METHOD OF DETERMINING A CHEMOTHERAPEUTIC REGIMEN FOR NON-SMALL-CELL LUNG CANCER BASED ON BRCA1 EXPRESSION - The present invention relates to a screening method for classifying patients and for selecting an effective chemotherapy for the treatment of a patient suffering from non-small-cell lung cancer (NSCLC), based on the use of his levels of BRCA1 expression to predict the outcome of chemotherapy. | 01-14-2010 |
20100167297 | METHOD OF DETERMINING THE TIME TO PROGRESSION OF NON SMALL CELL LUNG CANCER AFTER CHEMOTHERAPY BASED ON THIOREDOXIN EXPRESSION - The present invention relates to a method for predicting the Time to Progression (TTP) of non small cell lung carcinoma (NSCLC) patients treated with chemotherapy, based on the detecting the levels of expression of thioredoxin (TRX) in a biological sample of the patient, or based on simultaneously detecting the expression levels of thioredoxin and the methylation status of the 14-3-3σgene. | 07-01-2010 |
20110059459 | BRCA1 mRNA EXPRESSION PREDICTS SURVIVAL IN PATIENTS WITH BLADDER CANCER TREATED WITH NEOADJUVANT CISPLATIN-BASED CHEMOTHERAPY - The invention relates to methods for predicting the clinical outcome of a patient which suffers from bladder cancer based on the expression levels of BRCA1 wherein high BRCA1 expression levels are indicative of a poor prognosis. Moreover, the invention relates to methods for predicting the response to chemotherapy of a patient which suffers from bladder cancer based on the expression levels of BRCA1, in particular, in patients which have been treated with chemotherapy prior to surgical removal of the tumor. | 03-10-2011 |
20110086355 | BRCA1 mRNA EXPRESSION LEVELS PREDICT SURVIVAL IN BREAST CANCER PATIENTS TREATED WITH NEOADJUVANT CHEMOTHERAPY - The invention relates to methods for predicting the clinical outcome of a patient which suffers from breast cancer based on the expression levels of BRCA1, wherein low BRCA1 expression levels are indicative of a good prognosis. Moreover, the invention relates to methods for predicting the response to a neoadjuvant therapy based on a combination of an anti-metabolite, an intercalating agent and an alkylating agent of a patient which suffers from breast cancer based on the expression levels of BRCA1. | 04-14-2011 |
20110142961 | METHODS AND REAGENTS FOR PREDICTING CLINICAL OUTCOME AND CUSTOMIZING CHEMOTHERAPY IN LUNG CANCER PATIENTS - The invention relates to methods for the prediction of the clinical outcome of a patient suffering from cancer based on the relative expression levels of BRCA1 and RAP80 genes. The invention also relates to anticancer combination therapies comprising a platinum-based chemotherapeutic agent and an inhibitor of RAP80. | 06-16-2011 |
20120316187 | MOLECULAR BIOMARKERS FOR PREDICTING RESPONSE TO TYROSINE KINASE INHIBITORS IN LUNG CANCER - The invention relates to a method for predicting the response to the treatment with an EGFR tyrosine kinase inhibitor of a patient suffering lung cancer an carrying a mutation in the EGFR gene based on the expression levels in a sample of said patient of the BRCA1 gene wherein low BRCA1 expression levels are indicative of a positive response of a patient. This positive response is also observed in patients showing the T790M mutation in the EGFR gene which is usually associated with resistance to EGFR tyrosine kinase inhibitors. | 12-13-2012 |
20150038520 | Molecular Biomarkers for Predicting Response to Tyrosine Kinase Inhibitors in Lung Cancer - The invention relates to methods for determining the clinical outcome of patients suffering lung cancer and being under treatment with an EGFR inhibitor. The methods are based on the detection of the presence of mutations in the EGFR gene conferring resistance to inhibitors of the EGFR tyrosine kinase activity, wherein the appearance of said mutations in the biofluid of the patient is indicative of a high probability that the patient suffers a relapse of the disease. The invention also provides therapeutic methods for said patients. | 02-05-2015 |
Patent application number | Description | Published |
20090068657 | METHOD OF PREDICTING THE CLINICAL RESPONSE TO CISPLATIN OR CARBOPLATIN CHEMOTHERAPEUTIC TREATMENT - Method for predicting the survival of a patient suffering from NSCLC to a cisplatin or carboplatin based chemotherapy treatment which comprises the step of determining the methylation state of a nucleic acid encoding 14-3-3 sigma in a biological sample from the patient, wherein the presence of methylation is indicative of longer survival of said patient as a response to said chemotherapy treatment. The methylation status of the 14-3-3 sigma gene can be easily determined in a serum sample. | 03-12-2009 |
20090264641 | METHOD FOR THE ISOLATION OF MRNA FROM FORMALIN FIXED, PARAFFIN-EMBEDDED TISSUE - The invention provides a reliable method for recovering RNA from a formalin-fixed, paraffin-embedded biological tissue sample comprising:
| 10-22-2009 |
20100009360 | METHOD FOR THE DETECTION OF EGFR MUTATIONS IN BLOOD SAMPLES - The present invention refers to the detection of EGFR mutations in a blood (serum/plasma) sample from a subject. The method comprises: (i) obtaining the DNA from said sample; (ii) amplifying the nucleic acid sequence corresponding to a specific region of the EGFR gene by means of PCR using a Protein-Nucleic Acid probe; 10 and (iii) detecting said mutation. | 01-14-2010 |
20100167296 | METHOD OF DETERMINING A CHEMOTHERAPEUTIC REGIME AND SURVIVAL EXPECTANCY FOR NON SMALL CELL LUNG CANCER BASED ON EGFR/CSF-1/CA IX EXPRESSION - The present invention relates to a screening method for classifying and for deciding to apply chemotherapy to patients suffering from non-small-cell lung cancer (NSCLC), based on detecting the levels of EGFR, CSF-1 and CA IX. | 07-01-2010 |
20100267732 | Prognostic Molecular Markers for ET-743 Treatment - The present invention relates to the use of ecteinascidin 743 in human patients having certain molecular markers profile which has been associated with the outcome of ET-743 chemotherapy. In particular, the invention relates to the use of ecteinascidin 743 in patients having high expression levels of XPG mRNA or protein and/or having a “wild type” genotype for Asp1104His SNP of XPG gene. | 10-21-2010 |
20100286187 | METHOD OF PREDICTING SURVIVAL OF A NON-SMALL-CELL LUNG CANCER PATIENT TO A CHEMOTHERAPEUTIC TREATMENT - Method for predicting the survival of a patient suffering from NSCLC to an antimicrotubule agent based chemotherapy treatment which comprises the step of determining the methylation state of a nucleic acid encoding CHFR in a biological sample from the patient, wherein the presence of methylation is indicative of longer survival of said patient as a response to said chemotherapy treatment. The methylation status of the CHFR gene can be easily determined in a serum sample. | 11-11-2010 |
20140113293 | METHOD FOR THE DETECTION OF EGFR MUTATIONS IN BLOOD SAMPLES - The present invention refers to the detection of EGFR mutations in a blood (serum/plasma) sample from a subject. The method comprises:
| 04-24-2014 |